Stanford researcher Genovese joins Gilead to lead NASH, arthritis programs

Gilead Sciences is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its nonalcoholic steatohepatitis (NASH), fibrosis and arthritis pipeline programs.

Genovese has spent more than two decades at Stanford, most recently as the James W. Raitt Professor of Medicine and clinical chief in the division of immunology and rheumatology.